<DOC>
	<DOCNO>NCT00257348</DOCNO>
	<brief_summary>The purpose study evaluate effectiveness side effect drug capecitabine docetaxel treatment cervical cancer . Capecitabine approve FDA treatment breast colon cancer . Docetaxel approve treatment breast lung cancer . The use capecitabine docetaxel study treatment cervical cancer consider investigational . Eligible subject take drug capecitabine ( Xeloda ) mouth twice day every 12 hour , fourteen consecutive day follow 7 day rest period . Subjects also receive drug docetaxel ( Taxotere ) intravenously ( vein ) every three week .</brief_summary>
	<brief_title>Capecitabine Docetaxel Advanced/Recurrent Cervical Cancer</brief_title>
	<detailed_description />
	<mesh_term>Uterine Cervical Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<criteria>1 . Patients must histologically prove stage IVB , recurrent persistent squamous cell carcinoma , adenosquamous carcinoma , adenocarcinoma cervix amenable curative treatment surgery and/or radiation therapy 2 . Age great equal 18 3 . All patient must measurable disease . Measurable disease define least one lesion accurately measure least one dimension ( long dimension record ) . Each lesion must great equal 20 mm measure conventional technique , include palpation , plain xray , CT , MRI , great equal 10 mm measure spiral CT. Biopsy confirmation require lesion measure &lt; 30 mm treat physician determines clinically indicate . Patients must least one `` target lesion '' use assess response protocol define Response Evaluation Criteria Solid Tumors ( RECIST ) . This lesion one biopsied one performed . Patients tumor within outside previously irradiated field lesion outside irradiated area preferentially designate `` target '' lesion . 4 . Patients must adequate : Hematologic function : ANC great equal 1500/mm3 ; Platelets great equal 100,000/mm3 ; Hemoglobin great equal 8.0 g/dl Renal function : Serum creatinine less equal 1.2 mg/dl . Patients serum creatinine great 1.2 mg/dl less 1.5 mg/dl must 24hour creatinine clearance determination &gt; 50 cc/min eligible . Hepatic function : Total Bilirubin must within normal limit . Transaminases ( SGOT and/or SGPT ) may 2.5 x institutional upper limit normal ( ULN ) alkaline phosphatase less equal ULN , alkaline phosphatase may 4 x ULN transaminases less equal ULN 5 . Patients must GOG Performance Status 0 1 . 6 . Patients must recover effect surgery , radiation therapy , chemoradiotherapy . At least six week must elapse last administration chemoradiotherapy , least three week must elapse last administration radiation therapy alone . 7 . Patients must sign approve informed consent form . 8 . Patients must free clinically active infection . 9 . Women childbearing potential must negative pregnancy test . Women childbearing potential must willing consent use effective contraception treatment reach menopause . 1 . Patients bilateral hydronephrosis alleviate ureteral stent percutaneous drainage . Patients serum creatinine great 1.2 mg/dl less 1.5 mg/dl 24hour creatinine clearance determination &lt; 50 cc/min . 2 . Patients serum creatinine 1.5 mg/dl great . 3 . Patients previously treat chemotherapy except use concurrently radiation therapy 4 . Patients history severe hypersensitivity reaction docetaxel , drug formulate polysorbate 80 , fluoropyrimidine therapy 5FU . 5 . Patients pregnant lactate 6 . Patients craniospinal metastasis history craniospinal metastasis . 7 . Patients concomitant malignancy nonmelanoma skin cancer . 8 . Patients prior invasive malignancy ( except nonmelanoma skin cancer ) evidence disease within last 5 year whose prior malignancy treatment contraindicate current protocol therapy .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>Advanced Cervical Carcinoma</keyword>
	<keyword>Recurrent Cervical Carcinoma</keyword>
</DOC>